

Research Article

Expanded alleles of the *FMR1* gene are related to unexplained recurrent miscarriages

Xin-hua Wang^{1,2}, Xiao-hua Song³, Yan-lin Wang², Xing-hua Diao², Tong Li⁴, Qing-chun Li², Xiang-hui Zhang² and Xiao-hui Deng¹

¹Department of Reproductive Medical Center, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China; ²Department of Reproductive Medicine, Affiliated Hospital of Binzhou Medical College, Binzhou, Shandong 256603, China; ³Department of Obstetrics and Gynecology, Binzhou People's Hospital, Binzhou, Shandong 256610, China; ⁴Xinshijie Zhongxing Eye Hospital, Shanghai 200050, China

Correspondence: Xiao-hui Deng (xhdeng_med@126.com) or Yan-lin Wang (docylwang2003@126.com)



Up to 50% of recurrent miscarriage cases in women occur without an underlying etiology. In the current prospective case-control study, we determined the impact of CGG trinucleotide expansions of the fragile-X mental retardation 1 (*FMR1*) gene in 49 women with unexplained recurrent miscarriages. Case group consisted of women with two or more unexplained consecutive miscarriages. Blood samples were obtained and checked for the presence of expanded alleles of the *FMR1* gene using PCR. Patients harboring the expanded allele, with a threshold set to 40 repeats, were further evaluated by sequencing. The number of abortions each woman had, was not associated with her respective CGG repeat number ($P=0.255$). The repeat sizes of CGG expansion in the *FMR1* gene were significantly different in the two population groups ($P=0.027$). All the positive cases involved intermediate zone carriers. Hence, the CGG expanded allele of the *FMR1* gene might be associated with unexplained multiple miscarriages; whether such an association is coincidental or causal can be confirmed by future studies using a larger patient cohort.

Introduction

Involuntary loss of pregnancy in the first 24 weeks before the fetus is viable is termed as miscarriage. Recurrent miscarriage is defined as three or more consecutive pregnancy losses and is seen in 1% of women becoming pregnant [1-3]. There are multiple causes of recurrent miscarriage, involving genetic predisposition, anatomical, infectious, immunological, hematological, and endocrinology-related factors. However, etiology is unknown in 50% of recurrent miscarriage cases [4].

The fragile-X mental retardation 1 (*FMR1*) gene is located in the X chromosome, and encodes the fragile-X mental retardation protein (FMRP), an RNA-binding protein that regulates translation by regulating mRNA export between the cytoplasm and nucleus [5]. FMRP is required for normal neural development. *FMR1* gene mutations involve an expansion of CGG trinucleotide repeat region in the 5'-UTR [5] of *FMR1* mRNA. Fragile-X syndrome, premature ovarian failure (POF), and fragile X-associated tremor-ataxia syndrome (FXTAS) are different diseases associated with CGG expansion and each one is characterized by a different degree of this expansion [6].

Normal people carry up to 54 CGG repeats, while full mutation refers to more than 200 repeats. An expansion from 55 to 200 is called premutation, while the presence of 41-54 repeats is termed as the 'gray' or intermediate zone [7,8]. The prevalence of premutation is approximately 1 to 250 women [9], which can reach up to 1 to 110 in specific populations [10]. The intermediate zone can be found in 1 to 57 women [11]. Premutation with 55-200 CGG repeats has been shown to be related to POF [12]. Hence, the objective of the current study was to determine if CGG repeat expansion is associated with the risk of miscarriage.

Received: 25 May 2017
Revised: 09 October 2017
Accepted: 19 October 2017

Accepted Manuscript Online:
20 October 2017
Version of Record published:
23 November 2017

Table 1 Inclusion and exclusion criteria used in the current study

Inclusion criteria	
Cases	
<ul style="list-style-type: none"> • Age at recruitment <40 years • Two or more consecutive pregnancy losses up to completion of 20 weeks of pregnancy (with/without prior successful pregnancy) 	
Controls	
<ul style="list-style-type: none"> • Age at recruitment <40 years • History of documented normal pregnancies 	
Exclusion criteria	
Cases	
<ul style="list-style-type: none"> • History of abortion due to infection (TORCH, syphilis, HBV, HCV, HIV) • Currently in pregnancy or puerperium (6-week postpartum) • Diagnosis of thrombophilia (hereditary or acquired) • History of deep vein thrombosis or pulmonary • Diagnosed anatomical abnormalities of the uterus or fallopian tubes (including submucosal fibroids, uterine septum, Asherman syndrome) • History of cervical insufficiency • History of surgical procedures in the pelvis (excluding cesarean section) • History of alcohol/drug abuse • History of cancer • Abnormal chromosomal karyotype (in the couple) • Abnormal controls • History of pregnancy loss • Use of assisted reproduction technology 	
TORCH=toxoplasma gondii, rubella virus, cytomegalovirus herpes simplex virus; HBV=hepatitis B virus; HCV=hepatitis C virus	

Table 2 Summary characteristics and results in the study population

	Cases	Controls	P-value
<i>n</i>	57	57	
Age (years)	33 (28–39)	33 (29–38)	0.906
Miscarriages	2.52 ± 0.63	–	
Women with three or more miscarriages	23 (40%)		
CGG repeats*	35 (31–38)	31 (30–33)	0.017
CGG repeats†	29 (26–31)	28 (25–28)	0.027
Intermediate zone (41–54 CGG repeats)	4	1	0.168
Odds ratio: 4.167			

Continuous variables are presented as median (25–75th percentile) or mean ± S.D. and dichotomous variables as *n* (%); * estimated by electrophoresis analysis; † calculated by linear regression analysis.

Methods

Patients

The study was approved by the Institutional Review Board of Affiliated Hospital of Binzhou Medical College, and was conducted in accordance with the Declaration of Helsinki. The study population was recruited between 1 January 2014 and 31 December 2016 from recurrent miscarriage outpatient clinic of Affiliated Hospital of Binzhou Medical College of China. Inclusion and exclusion criteria are summarized in Table 1. The inclusion and exclusion criteria were stringent to minimize the risk of bias, a problem inherent in retrospective studies. Data from their medical records were obtained and additional laboratory examinations were ordered, when needed. The control group consisted of women from the outpatient gynecological clinic at the Affiliated Hospital of Binzhou Medical College of China, visiting for routine diagnostic checkup, as well as female members of hospital staff, age matched within 2 years, on a 1:1 ratio. Recurrent miscarriage in the present study was considered the presence of at least two consecutive pregnancy losses.

Table 3 Distribution number (#) of miscarriages in the included study population

# of miscarriages	Cases	% of cases group
2	34	59.6
3	17	29.8
4	5	8.8
5	1	1.8
	57	100




Figure 1. Representative gel electrophoresis analysis of PCR products

Shown are different repeat numbers.

PCR analysis

Genomic DNA was isolated from peripheral blood leukocytes using an affinity purification method following manufacturer's recommendation (Thermo Fisher Scientific, Shanghai, China). Genomic DNA samples were tested for the presence of an expansion in the CGG trinucleotide repeat region using a two-step PCR protocol [13]. In the first step, genomic DNA was amplified using PCR, with the following primers: forward: 5'- GCTCAGCTCCGTTTCGGTTTCACTTCCGGT-3' and reverse: 5'-AGCCCCGCACTTCCACCACCAGCTCCTCCA-3', a primer pair that flanks the CGG repeat region, using betaine as the osmolite14 and the Expand Long Template PCR System from Roche Diagnostics. The reaction mixtures were 500 $\mu\text{mol/l}$ dNTPs, 0.20 μM of each primer, 50 ng of genomic DNA, and 2.2 M betaine.

The final PCR products were resolved by electrophoresis in 2.5% agarose gel in the presence of Ethidium Bromide for 1 h at 40 V. The expected PCR product with this method was 221 bp, excluding the CGG repeat region. The cutoff for identification of the positive cases was set at 41 repeats. Thus, the presence of a band between 344 and 383 bp defined 'the gray zone', while a band between 384 and 821 bp the 'premutation state'. Gel analysis was performed using Image Lab software (Bio-Rad). The results marked as positive were verified with sequencing analysis to confirm the length of the expanded alleles. All PCR reactions that produced a single band were subsequently analyzed with the second PCR step, using the reverse primer mentioned above and the CGG-chimeric primer (5'-AGCGTCTACTGTCTCGGCACTTGCCCCGCCGCCGCG-3'), under the same conditions. Of note, the 3' end sequence of the chimeric primer (CCGCCGCCGCCG) has the potential to bind randomly in the CGG repeat region, and thus to produce a 'smear' on the gel, in the presence of expanded mutated alleles that were not amplified in the first step [14].

Sequencing analysis

All PCR fragments, from the specimens that were considered as positive, were gel isolated, purified, and further analyzed by dideoxy-termination sequencing method performed by a locally available sequencing core to accurately measure the number of the repeats.

Table 4 Measured number (n) of CGG repeats using electrophoresis compared with sequencing analysis, on cases marked as positive (one case was measured as normal, <41 repeats)

n of CGG repeats	Cases						Controls
Electrophoresis	46	50	55	58	65	57	
Sequencing analysis	38	42	44	44	47	46	




Figure 2. Linear regression analysis of electrophoresis compared with sequencing, as methods of measuring CGG repeats
 One out of six cases did not get validated by the sequencing analysis; hence there are 11 instead of 12 data points.

Statistical analysis

Statistical analysis was performed using IBM SPSS Statistics v21. Continuous data were described either as median or mean \pm S.D. – frequencies as *n* (%). Comparison between groups in continuous variables was performed using Mann–Whitney test and comparison amongst more than two groups was performed using the Kruskal–Wallis test. A model of linear regression was created, for predicting values, after accurately measuring a number of them by sequencing. Significance level was set to 0.05.

Results

Following screening process as mentioned in the inclusion criteria, a total of 57 cases were selected and another 57 controls were recruited, age matched (within ± 2 years). The major characteristics of the study population and the main results are summarized in Table 2. The women in the patient group had two up to five miscarriages (average 2.52 ± 0.63). The percentage of women with two miscarriages was 59.6%, with three miscarriages 29.8%, with four miscarriages 8.8%, and with five miscarriages 1.8% (Table 3). The number of miscarriages each woman had was not associated with the number of the CGG repeats (Kruskal–Wallis test, $P=0.255$).

Analysis of the first PCR step amplicons revealed a distinct, two band patterns in 34 out of 57 of patients and 22 out of 57 of control samples (Figure 1, representative figure). The samples that showed a ‘single band’ were further analyzed with the second PCR step to distinguish homozygosity, from the presence of a mutated allele not amplified in the first step. No mutated allele was detected. For each woman in the study, the band representing the highest number of CGG repeats was taken into account.

Five women from the patients group (7.01%) were identified to carry the expanded allele – 46, 50, 55, 58, and 65 repeats (two intermediate zone and three premutation carriers), while only one woman in the control group (1.75%) was identified to carry an expanded allele with 57 repeats (premutation). The reported prevalence of intermediate zone carriers is up to approximately 1/57 (1.75%) as mentioned before. The two groups do not differ in terms of number of women marked positive for premutation (Chi-square, $P=0.168$, odds ratio =4.167, ci 0.459–39.629). The number of repeats of the two population groups were significantly different (Mann–Whitney test, $P=0.027$).

In order to determine the exact number of repeats present in each allele, the positive cases were evaluated by sequencing. Except for one case within the miscarriage group, all the remaining five had intermediate zone CGG expansion, extending from 42 to 47 repeats (Table 4).

Table 5 Total number of CGG repeats including both bands after regression analysis

CASE ID <i>n</i>	Cases		Controls ID <i>n</i>	Controls	
	First band	Second band		First band	Second band
1	27	25	101	25	25
2	27	27	102	27	24
3	28	27	103	25	25
4	28	26	104	28	17
5	26	20	105	25	25
6	27	27	106	27	24
7	33	25	107	28	28
8	26	19	108	30	18
9	26	26	109	22	22
10	28	27	110	29	21
11	25	22	111	20	20
12	25	25	112	27	27
13	44	31	113	24	21
14	25	25	114	29	20
15	27	25	115	27	27
16	33	26	116	27	24
17	25	25	117	27	27
18	29	29	118	27	27
19	33	30	119	25	25
20	35	22	120	27	25
21	47	38	121	24	24
22	38	34	122	25	25
23	20	20	123	27	20
24	26	24	124	29	20
25	25	25	125	27	27
26	25	23	126	29	22
27	32	17	127	26	26
28	44	15	128	26	23
29	30	28	129	25	25
30	19	19	130	32	28
31	26	19	131	28	28
32	28	20	132	27	24
33	30	20	133	26	26
34	42	27	134	20	20
35	35	33	135	28	26
36	28	20	136	31	24
37	28	20	137	23	23
38	32	28	138	24	24
39	29	28	139	29	20
40	26	26	140	27	27
41	25	25	141	28	28
42	27	25	142	46	22
43	28	28	143	27	27
44	29	19	144	27	20
45	30	25	145	24	24
46	31	26	146	27	24
47	24	24	147	22	22
48	24	24	148	29	20
49	30	19	149	20	20
50	28	20	150	29	29
51	21	21	151	23	19
52	32	24	152	25	20
53	32	25	153	28	23
54	29	23	154	26	22

Continued over

Table 5 Total number of CGG repeats including both bands after regression analysis (Continued)

CASE ID <i>n</i>	Cases		Controls ID <i>n</i>	Controls	
	First band	Second band		First band	Second band
<u>55</u>	31	25	<u>155</u>	25	19
<u>56</u>	28	28	<u>156</u>	24	23
<u>57</u>	27	23	<u>157</u>	25	21

Underline represents the positive cases (four in cases and one control).

Even though electrophoresis results were largely consistent with sequencing analysis, PCR-based analysis did result in an overestimation in each case, with one out of six cases not getting validated by the sequencing analysis. A regression model in SPSS was used to plot divergence between the two methodologies and linear regression was found to be a good fit (Figure 2), which was then used for CGG repeat prediction in all 114 cases and controls in the current study (Table 5).

Discussion

In the present study, we examine the presence of expanded CGG alleles in women with unexplained recurrent miscarriages. These women have significantly more CGG repeats at their *FMR1* gene, than women with documented normal fertility.

It is well known that women with premutations of the *FMR1* gene are likely to develop POF in up to 20% of cases [15]. On the contrary, women with intermediate length alleles do not seem to carry this risk [16]. Since none of the women in this study had a premutation of the *FMR1* gene, we cannot attribute the number of miscarriages directly to POF.

FMR1 alleles with the size of 45 to 200 are meiotic unstable and can be inherited as such or with increased size in the offspring [17], and also the *FMR1* gene undergoes abnormal methylation [18,19]. It is possible that these unstable mutations can result in defects that are incompatible with life, and lead to miscarriage. This could be proven by performing DNA analysis in the products of conception, in women with recurrent miscarriages, looking for expanded alleles or an otherwise altered *FMR1* gene (e.g. methylation).

The mechanism of meiotic instability of the *FMR1* gene occurs only during meiosis in oocytes and not in sperm [20]. Therefore, women with premutations can have daughters with full mutations, whereas men can only pass premutations to their daughters as such. So, it seems reasonable to focus screening to women, when examining couples for expanded CGG alleles.

The present study has its own limitations. As it is a case-control study, it is vulnerable to bias. Also, secondary causes of recurrent miscarriages have potential confounding effects and cannot be ruled out. Recurrent miscarriages are a cause of significant distress for the affected couples, and pose a diagnostic and therapeutic challenge for the physicians involved. This is especially true for the cases that remain unexplained, after the full diagnostic workup (approximately 50%). It is possible that the presence of a CGG expanded allele could explain a number of them. To our knowledge, there is no other similar study in the medical literature. More studies are needed toward this hypothesis in the future, which could verify it, and uncover the molecular mechanism responsible.

Competing interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This work was supported by the Project of Binzhou Medical College (expression of vaspin in patients with polycystic ovary syndrome and preliminary study on proliferation and apoptosis of human ovarian granulosa cells from Dr X.-h.W.) [grant number BY2014KJ4]; and the Natural Science Foundation of Shandong Province (determination of nesfatin-1 in patients with polycystic ovary syndrome and its effect on granulosa cells from Dr Y.-l.W.) [grant number ZR2012HL03].

Author contribution

X.-h.W and X.-h.S prepared the manuscript and participated in the data analysis. T.L. was involved in the data analysis. X.-h.D., Q.-c.L., and X.-h.Z collected data. Y.-l.W and X.-h.D designed the present study and guided the data analysis. All authors have read and approved the final manuscript.

Abbreviations

CI, confidence interval; *FMR1*, fragile-X mental retardation 1; FMRP, fragile X mental retardation protein; FXTAS, fragile-X associated tremor-ataxia syndrome; POF, premature ovarian failure.

References

- 1 Dhont, M. (1990) Recurrent miscarriage. *Am. J. Perinatol.* **336**, 673–675
- 2 Nolin, S.L., Brown, W.T., Glicksman, A., Houck, Jr, G.E., Gargano, A.D., Sullivan, A. et al. (2003) Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. *Am. J. Hum. Genet.* **72**, 454–464
- 3 Practice Committee of American Society for Reproductive Medicine (2013) Definitions of infertility and recurrent pregnancy loss. *Fertil. Steril.* **99**, S60
- 4 Christiansen, O.B., Andersen, A.M.N., Bosch, E., Daya, S., Delves, P.J., Hviid, T.V. et al. (2005) Evidence-based investigations and treatments of recurrent pregnancy loss. *Fertil. Steril.* **83**, 821–839
- 5 Crawford, D.C., Acuna, J.M. and Sherman, S.L. (2001) FMR1 and the fragile X syndrome: human genome epidemiology review. *Genet. Med.* **3**, 359–371
- 6 Willemsen, R., Levenga, J. and Oostra, B.A. (2011) CGG repeat in the FMR1 gene: size matters. *Clin. Genet.* **80**, 214–225
- 7 Loesch, D. and Hagerman, R. (2012) Unstable mutations in the FMR1 gene and the phenotypes. *Adv. Exp. Med. Biol.* **769**, 78–114
- 8 Sherman, S., Pletcher, B.A. and Driscoll, D.A. (2005) Fragile X syndrome: diagnostic and carrier testing. *Genet. Med.* **7**, 584–587
- 9 Rousseau, F., Rouillard, P., Morel, M.L., Khandjian, E.W. and Morgan, K. (1995) Prevalence of carriers of premutation-size alleles of the FMR1 gene—and implications for the population genetics of the fragile X syndrome. *Am. J. Hum. Genet.* **57**, 1006–1018
- 10 Toledano-Alhadeff, H., Basel-Vanagaite, L., Magal, N., Davidov, B., Ehrlich, S., Drasinover, V. et al. (2001) Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. *Am. J. Hum. Genet.* **69**, 351–360
- 11 Cronister, A., Teicher, J., Rohlf, E.M., Donnenfeld, A. and Hallam, S. (2008) Prevalence and instability of fragile X alleles: implications for offering fragile X prenatal diagnosis. *Obstet. Gynecol.* **111**, 596–601
- 12 Sullivan, A.K., Marcus, M., Epstein, M.P., Allen, E.G., Anido, A.E., Paquin, J.J. et al. (2005) Association of FMR1 repeat size with ovarian dysfunction. *Hum. Reprod.* **20**, 402–412
- 13 Tassone, F., Pan, R., Amiri, K., Taylor, A.K. and Hagerman, P.J. (2008) A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. *J. Mol. Diagn.* **10**, 43–49
- 14 Saluto, A., Brussino, A., Tassone, F., Arduino, C., Cagnoli, C., Pappi, P. et al. (2005) An enhanced polymerase chain reaction assay to detect pre- and full mutation alleles of the fragile X mental retardation 1 gene. *J. Mol. Diagn.* **7**, 605–612
- 15 Sherman, S.L. (2000) Premature ovarian failure in the fragile X syndrome. *Am. J. Med. Genet.* **97**, 189–194
- 16 Kline, J.K., Kinney, A.M., Levin, B., Brown, S.A., Hadd, A.G. and Warburton, D. (2014) Intermediate CGG repeat length at the FMR1 locus is not associated with hormonal indicators of ovarian age. *Menopause* **21**, 740–748
- 17 Nolin, S.L., Lewis, III, F.A., Ye, L.L., Houck, Jr, G.E., Glicksman, A.E., Limprasert, P. et al. (1996) Familial transmission of the FMR1 CGG repeat. *Am. J. Hum. Genet.* **59**, 1252–1261
- 18 Bell, M.V., Hirst, M.C., Nakahori, Y., MacKinnon, R.N., Roche, A., Flint, T.J. et al. (1991) Physical mapping across the fragile X: hypermethylation and clinical expression of the fragile X syndrome. *Cell* **64**, 861–866
- 19 Oberle, I., Rousseau, F., Heitz, D., Kretz, C., Devys, D., Hanauer, A. et al. (1991) Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. *Science* **252**, 1097–1102
- 20 Martin, J.R. and Arici, A. (2008) Fragile X and reproduction. *Curr. Opin. Obstet. Gynecol.* **20**, 216–220